| [1] |
Motz WH, Strauer BE. Differential therapy of hypertensive heart disease[J]. Am J Cardiol, 1990, 65(14):60G-64G.
|
| [2] |
杨玺. 高血压并发心力衰竭的治疗[J]. 临床荟萃, 1992, 7(7):312-313.
|
| [3] |
黄明辉, 胡钰, 汤玲玲, 等. 高血压在射血分数保留的心力衰竭发展中的作用[J]. 心血管病学进展, 2019, 40(2):293-296.
|
| [4] |
曹高镇, 汪润, 吴旻, 等. HFpEF、HFmrEF 和HFrEF 的临床特征及左心室重塑对比分析[J]. 现代生物医学进展, 2018, 18(17):3269-3273.
|
| [5] |
马孙晏, 夏东. 射血分数保留心力衰竭预后相关因素的研究进展[J]. 北京医学, 2021, 43(2):151-154.
|
| [6] |
马俊怡, 徐运. 高血压患者大脑的结构/功能MRI改变[J]. 中风与神经疾病杂志, 2020, 37(6):502-504.
|
| [7] |
韩蓓蓓, 沈成兴. 高血压并慢性心力衰竭的诊治新进展[J]. 世界临床药物, 2019, 40(7):461-469.
|
| [8] |
赵冬. 中国成人高血压流行病学现状[J]. 中国心血管杂志, 2020, 25(6):513-515.
|
| [9] |
殷国青, 周晓辉. 高血压流行病学研究现状[J]. 临床医药文献杂志, 2018, 5(4):189-192.
|
| [10] |
吴琦欣, 史明标, 邓燕, 等. 我国成人高血压流行病学分布特征研究进展[J]. 现代预防医学, 2019, 46(23):4238-4242.
|
| [11] |
张存新, 陈俊华. 沙库巴曲缬沙坦治疗原发性高血压并射血分数保留心力衰竭的疗效[J]. 武警医学, 2020, 31(12):1017-1020.
|
| [12] |
吴伏鹏, 封启明. 射血分数保留型心力衰竭发病机制的研究进展[J]. 医学综述, 2020, 26(22):4467-4472.
|
| [13] |
金彩彩, 张晓伟. 抗心衰天然药物及活性化合物研究进展[J]. 药学学报, 2020, 55(6):1147-1156.
|
| [14] |
Verloop WL, Beeftink MMA, Santema BT, et al. A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fraction[J]. PLoS One, 2015, 10(2):e0117332.
doi: 10.1371/journal.pone.0117332
URL
|
| [15] |
高可, 杨蕾, 姚新叶, 等. 射血分数保留性心力衰竭动物模型的研究进展[J]. 心血管病学进展, 2020, 41(8):834-838.
|
| [16] |
Zhao Y, Ma R, Yu X, et al. AHU377+valsartan (LCZ696) modulates renin-angiotensin system (RAS) in the cardiac of female spontaneously hypertensive rats compared with valsartan[J]. J Cardiovasc Pharmacol Ther, 2019, 24(5):450-459.
doi: 10.1177/1074248419838503
URL
|
| [17] |
曹李媛, 史浩颖, 戴秋艳. 高血压致左室射血分数正常者心力衰竭的发病机制[J]. 上海交通大学学报(医学版), 2010, 3(30):343-347.
|
| [18] |
Fujimoto N, Onishi K, Dohi K, et al. Hemodynamic characteristics of patients with diastolic heart failure and hypertension[J]. Hypertens Res, 2008, 31(9):1727-1735.
doi: 10.1291/hypres.31.1727
pmid: 18971551
|
| [19] |
Borbely A, van der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure[J]. Circulation, 2005, 111(6):774-781.
doi: 10.1161/01.CIR.0000155257.33485.6D
URL
|
| [20] |
Zile MR, Baicu CF, Ikonomidis JS, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin[J]. Circulation, 2015, 131(14):1247-1259.
doi: 10.1161/CIRCULATIONAHA.114.013215
URL
|
| [21] |
高鹏, 袁杰. 射血分数保留心力衰竭的诊疗新进展[J]. 心血管康复医学杂志, 2020, 31(5):631-634.
|
| [22] |
Oktay AA, Shah SJ. Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons[J]. Curr Cardiol Rev, 2015, 11(1):42-52.
doi: 10.2174/1573403X09666131117131217
URL
|
| [23] |
Zheng SL, Chan FT, Nabeebaccus AA, et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: A systematic review and meta-analysis[J]. Heart, 2018, 104(5):407-415.
doi: 10.1136/heartjnl-2017-311652
pmid: 28780577
|
| [24] |
Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials[J]. Eur Heart J, 2018, 39(1):26-35.
doi: 10.1093/eurheartj/ehx564
pmid: 29040525
|
| [25] |
Patel K, Fonarow GC, Ahmed M, et al. Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction[J]. Circ Heart Fail, 2014, 7(6):945-952.
doi: 10.1161/CIRCHEARTFAILURE.114.001301
URL
|
| [26] |
Kiuchi S, Hisatake S, Kabuki T, et al. Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction[J]. Clin Exp Hypertens, 2017, 39(4):350-354.
doi: 10.1080/10641963.2016.1267198
URL
|
| [27] |
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)[J]. JAMA, 2002, 288(23):2981-2997.
doi: 10.1001/jama.288.23.2981
URL
|
| [28] |
郭娅娅, 尹发慧, 樊春蕾, 等. LCZ696在慢性心力衰竭治疗中的研究进展[J]. 中国综合临床, 2018, 34(1):92-95.
|
| [29] |
段骁睿, 李广平. 沙库巴曲缬沙坦抑制心脏重构的研究进展[J]. 天津医药, 2020, 48(12):1240-1243.
|
| [30] |
Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial[J]. Lancet, 2012, 380(9851):1387-1395.
doi: 10.1016/S0140-6736(12)61227-6
pmid: 22932717
|
